Dermata TherapeuticsNASDAQ: DRMA

– Dermata Therapeutics invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com – – Dermata Therapeutics invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com –

SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that the Company's CEO, Gerry Proehl, will present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, on Tuesday, October 15, 2024, at 3:30PM ET. Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management.

Dermata Therapeutics (NASDAQ: DRMA ) stock is taking off on Wednesday alongside heavy pre-market trading of the late-stage medical dermatology company's shares. This has more than 13 million shares of DRMA stock changing hands as of this writing.

- Company to provide a corporate overview followed by a live question and answer session - SAN DIEGO, CA / ACCESSWIRE / February 1, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will be featured as a presenting company at the Emerging Growth Conference on February 7, 2024. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Gerry Proehl in real time.

Dermata Therapeutics (NASDAQ: DRMA ) stock is soaring higher on Friday after the clinical-stage medical dermatology company announced a new patent in Japan. This new patent covers DMT410 for the treatment of hyperhidrosis.

Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.

SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced today that Dermata's CEO, Gerald Proehl, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET. The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space.

Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.

Dermata Therapeutics (NASDAQ: DRMA ) stock is on the rise Thursday following an update concerning its moderate-to-severe acne treatment. The big news here is the FDA signed off on the company's ability to hold a Phase 3 clinical trial of DMT310.